Moore M - Search Results

1

Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial.

Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A, Lo C. Zimmermann C, et al. Among authors: moore m. Lancet. 2014 May 17;383(9930):1721-30. doi: 10.1016/S0140-6736(13)62416-2. Epub 2014 Feb 19. Lancet. 2014. PMID: 24559581 Clinical Trial.

2

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer.

Moore MJ, Kaizer L, Erlichman C, Myers R, Feld R, Thiessen JJ, Fine S. Moore MJ, et al. Cancer Chemother Pharmacol. 1995;37(1-2):86-90. doi: 10.1007/BF00685633. Cancer Chemother Pharmacol. 1995. PMID: 7497602 Clinical Trial.

3

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Moore MJ, et al. J Clin Oncol. 1994 Apr;12(4):689-94. doi: 10.1200/JCO.1994.12.4.689. J Clin Oncol. 1994. PMID: 7512127 Clinical Trial.

4

A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.

Moore MJ, Erlichman C, Kaizer L, Fine S. Moore MJ, et al. Anticancer Drugs. 1993 Oct;4(5):555-7. doi: 10.1097/00001813-199310000-00004. Anticancer Drugs. 1993. PMID: 8292812 Clinical Trial.

5

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Tannock IF, et al. Among authors: moore mj. J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756. J Clin Oncol. 1996. PMID: 8656243 Clinical Trial.

6

Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against.

Jewett MA, Khakpour G, Moore MJ. Jewett MA, et al. Among authors: moore mj. Eur Urol. 1996;29 Suppl 2:45-8. doi: 10.1159/000473839. Eur Urol. 1996. PMID: 8717463 Review.

7

Overview of Canadian trials in hormonally resistant prostate cancer.

Moore MJ, Tannock IF. Moore MJ, et al. Semin Oncol. 1996 Dec;23(6 Suppl 14):15-9. Semin Oncol. 1996. PMID: 8996579 Review.

8

Other chemotherapy regimens including mitoxantrone and suramin.

Siu LL, Moore MJ. Siu LL, et al. Among authors: moore mj. Semin Urol Oncol. 1997 Feb;15(1):20-7. Semin Urol Oncol. 1997. PMID: 9050136 Review.

9

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Moore MJ, et al. J Clin Oncol. 1997 Dec;15(12):3441-5. doi: 10.1200/JCO.1997.15.12.3441. J Clin Oncol. 1997. PMID: 9396395 Clinical Trial.

10

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF. Bloomfield DJ, et al. Among authors: moore mj. J Clin Oncol. 1998 Jun;16(6):2272-9. doi: 10.1200/JCO.1998.16.6.2272. J Clin Oncol. 1998. PMID: 9626231 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results